Andre the Giant and Acromegaly: Growth Hormone Excess, Press Coverage, and Clinical Context

What Press Coverage Said About Andre the Giant's Size and Health

Press coverage of Andre the Giant during his active career (roughly 1970 to 1992) almost never used the word "acromegaly." Reporters described his dimensions in superlatives and attributed his size to genetics or an unspecified glandular condition. The clinical picture, however, was consistent with classical acromegaly throughout.

How Journalists Framed His Condition

Sports writers and entertainment journalists in the 1970s and 1980s referred to Andre simply as "the Eighth Wonder of the World," a promotional title that reinforced spectacle over medicine. Profiles in outlets such as Sports Illustrated and The New York Times noted his outsized hands, prominent brow ridges, and shoe size (size 22) without connecting those features to a diagnosable endocrine disorder.

A 1981 Sports Illustrated feature described Andre's dietary intake (reportedly 7,000 or more calories per day) and his alcohol consumption as quirks of a larger-than-life personality. No physician source was quoted. The piece did not mention pituitary disease.

Post-Death Coverage and the Clinical Shift

After Andre died on January 27, 1993, several obituaries did mention a "glandular disorder" or "giantism," though clinical specificity remained low. The shift toward genuine medical framing came decades later, through documentary work. The HBO documentary "Andre the Giant" (2018) included interviews with family members and wrestling colleagues who described progressive physical deterioration: increasing joint pain, difficulty walking, reliance on a back brace, and chronic fatigue. These features are consistent with the musculoskeletal and cardiovascular sequelae of long-standing acromegaly described in the endocrinology literature. Acromegaly causes arthropathy in up to 70% of patients, according to a review published in Endocrine Reviews [1].

What Andre Said in His Own Words

Andre gave relatively few interviews about his health. In a 1981 interview with journalist Bill Apter (republished in Pro Wrestling Illustrated), he acknowledged that his size caused him pain and that he expected a shortened life. He did not use medical terminology. That candor, understated as it was, stands as one of the clearest first-person acknowledgments on record that he understood his condition carried consequences.

No formal press statement from a treating physician was ever published during his lifetime, and no named clinician publicly discussed his case until after his death.

The Biology Behind Andre's Size: GH-Secreting Pituitary Adenomas

Understanding why Andre grew to 7 feet 4 inches requires understanding what a GH-secreting pituitary adenoma does to the body over decades of uncontrolled secretion.

Growth Hormone Physiology

The pituitary gland releases growth hormone (GH) in pulses, stimulated by hypothalamic GHRH and suppressed by somatostatin. GH then drives hepatic production of insulin-like growth factor 1 (IGF-1), which mediates most of GH's tissue effects. In normal adults, GH secretion is tightly regulated. IGF-1 levels in healthy adults typically fall between 100 and 300 ng/mL depending on age [2].

When a benign GH-secreting adenoma develops before epiphyseal closure (before puberty), the result is gigantism: linear bone growth continues beyond normal limits. When the adenoma develops or persists after epiphyseal closure, the condition is called acromegaly: bones widen rather than lengthen, soft tissues expand, and visceral organs enlarge. Andre's presentation, which began in childhood, produced both gigantism (extreme linear height) and the characteristic acromegalic features (jaw enlargement, hand and foot widening, coarse facial features) visible by his early adulthood.

IGF-1 as the Key Biomarker

The Endocrine Society's 2014 Clinical Practice Guideline on acromegaly specifies that a random serum IGF-1 elevated above the age- and sex-adjusted normal range is the primary screening test, and that a GH level that fails to suppress below 1 ng/mL after a 75-gram oral glucose load confirms the diagnosis [3]. Andre never received a formal published diagnosis in a peer-reviewed record, but his phenotype is textbook.

A population-based study in The Journal of Clinical Endocrinology and Metabolism (N=1,034 patients with acromegaly) found that the mean delay from symptom onset to diagnosis was 4.5 to 5 years, and that patients with macroadenomas had higher mean GH and IGF-1 levels at presentation [4]. Andre's case almost certainly involved a macroadenoma given his extreme phenotype, and his "diagnosis delay" was effectively his entire lifetime.

Cardiovascular Consequences

Acromegaly causes biventricular hypertrophy, diastolic dysfunction, and accelerated atherosclerosis. A meta-analysis of 16 studies (N=1,362) published in Circulation found that acromegalic cardiomyopathy is present in approximately 30% of patients with active disease [5]. Andre died of congestive heart failure at age 46, a death that is clinically consistent with the cardiovascular trajectory of uncontrolled, lifelong GH excess.

The Endocrine Society guideline states: "Cardiovascular disease is the leading cause of death in patients with acromegaly, and mortality correlates with the duration and degree of GH and IGF-1 excess" [3].

Did Andre the Giant Receive Any Treatment for His Condition?

No documented medical treatment for his GH excess appears in any published record or credible reporting. This is worth examining clinically, because effective treatments did exist during his adult lifetime.

Treatments Available During Andre's Career (1970 to 1993)

Transsphenoidal surgery became the first-line intervention for GH-secreting adenomas in the 1970s. Remission rates for microadenomas exceed 80%, though for macroadenomas the figure falls to 40 to 60% [6]. Given the size Andre's adenoma almost certainly reached, surgery alone may not have achieved biochemical cure, but it could have reduced GH output substantially.

Bromocriptine, a dopamine agonist, was the first pharmacological agent used for acromegaly and received FDA approval for that indication in 1978. Its GH-lowering efficacy is modest: normalizing IGF-1 in only about 10% of patients [7]. It was the best available medical option for most of the 1970s.

Octreotide, a somatostatin analogue, received FDA approval in 1988 [accessdata.fda.gov]. Clinical trial data showed octreotide normalized IGF-1 in approximately 65% of patients and reduced GH to below 2.5 ng/mL in about 60% [8]. Andre was still active in wrestling in 1988 and alive until 1993. He had, in principle, access to a drug that might have meaningfully reduced his GH burden and possibly extended his life. No reporting has ever established that he was offered or declined octreotide.

Why Treatment Was Likely Never Pursued

Several factors may explain the absence of documented treatment. First, diagnosis itself was probably never formally established. Second, Andre's career depended on his extraordinary size, and there is a documented pattern in entertainment medicine of performers avoiding diagnoses that might affect their work. Third, access to endocrinology subspecialty care was uneven in the 1970s and 1980s, particularly for someone who spent most of each year traveling internationally on a wrestling circuit.

These are inferences, labeled as such. No first-person statement from Andre about declining treatment has been published.

Acromegaly Mortality: What the Numbers Show

Andre's death at 46 is not an outlier for untreated acromegaly. The mortality data are consistent and sobering.

Standardized Mortality Ratios

A landmark study by Holdaway et al. Published in The Journal of Clinical Endocrinology and Metabolism (N=208 patients followed for a median of 16.9 years) found a standardized mortality ratio (SMR) of 1.72 for all-cause death in patients whose GH remained above 2.5 ng/mL after treatment, compared to an SMR approaching 1.0 in those achieving biochemical control [9]. For completely untreated patients over decades, the SMR is likely higher still.

A separate European multicenter registry study (N=1,362) published in Annals of Internal Medicine reported that cardiovascular disease accounted for 60% of deaths in acromegaly patients, with a mean age at death of 59 years in treated cohorts [10]. Andre died at 46, suggesting his disease course was more aggressive, possibly due to the early-onset gigantism component and the complete absence of any GH-lowering intervention.

Cardiac Mechanism

Excess GH and IGF-1 drive cardiomyocyte hypertrophy through direct receptor-mediated effects. Left ventricular mass index increases proportionally with IGF-1 levels. A study in Circulation (N=77 acromegaly patients vs. 30 matched controls) found that mean left ventricular mass index was 134 g/m² in active acromegaly vs. 89 g/m² in controls (P<0.001) [5]. Diastolic filling abnormalities progress to systolic dysfunction in the most severe and prolonged cases. Andre's reported symptoms in his final years (limited mobility, fatigue, difficulty breathing on exertion) are consistent with this progression.

Current Standard of Care: What Would Andre's Treatment Look Like Today?

If Andre presented to an academic endocrinology center in 2025 with his phenotype at, say, age 30, the management algorithm would look substantially different from anything available during his career.

First-Line Surgery

Transsphenoidal surgery, now performed endoscopically, remains the first-line recommendation per the 2014 Endocrine Society guideline [3]. For large or invasive macroadenomas, surgical debulking reduces tumor mass and lowers GH output even when full remission is not achieved. Postoperative IGF-1 and GH measurements at 12 weeks guide next steps.

Somatostatin Receptor Ligands

For patients who do not achieve biochemical remission after surgery, or who are poor surgical candidates, somatostatin receptor ligands (SRLs) are the primary medical therapy. Lanreotide autogel (Somatuline Depot) and octreotide LAR (Sandostatin LAR) are both FDA-approved. In the PRIMARYS trial (N=90), primary lanreotide therapy achieved IGF-1 normalization in 34.8% of patients at 48 weeks and reduced tumor volume by more than 20% in 63.3% of patients [11]. Long-acting formulations allow monthly subcutaneous dosing.

Pegvisomant as Adjunct Therapy

Pegvisomant, a GH receptor antagonist approved by the FDA in 2003, blocks GH signaling at the tissue level rather than suppressing GH secretion. In a multicenter study (N=112), pegvisomant normalized IGF-1 in 97% of patients at the highest tested dose [12]. It is typically reserved for patients who fail or partially respond to SRL therapy.

Radiation as Last Resort

Stereotactic radiosurgery (Gamma Knife or CyberKnife) is used for residual tumor not controlled by surgery or medication. Biochemical remission rates at 5 years range from 20% to 60% depending on pre-treatment GH levels, per a systematic review in Endocrine-Related Cancer [13]. Radiation carries a risk of hypopituitarism over time, requiring lifelong hormone replacement monitoring.

Why Andre the Giant's Case Remains Clinically Relevant

His case appears in medical education contexts precisely because it illustrates the full natural history of untreated GH excess: from gigantism in childhood, through progressive acromegalic features in adulthood, to fatal cardiomyopathy before age 50. Most patients seen in modern endocrinology clinics are diagnosed and treated earlier, so the complete untreated arc is rarely observed.

Teaching Points for Clinicians

Acromegaly has a mean diagnostic delay of 4.5 to 5 years even in contemporary medical systems, as documented in a 2014 systematic review in Pituitary (N=3,173 patients across 11 studies) [14]. That delay exists because the physical changes are gradual and often attributed to aging or body habitus. Andre's case is an extreme version of a problem that still occurs in attenuated form today: patients accumulate cardiovascular and metabolic damage during the years between symptom onset and treatment.

The Role of IGF-1 Screening

The Endocrine Society recommends IGF-1 screening in any patient with features suggestive of acromegaly: new-onset diabetes, carpal tunnel syndrome, jaw changes, shoe or ring size increase, or unexplained arthropathy [3]. Early detection allows surgical intervention when tumor size is still manageable and before irreversible cardiovascular remodeling has occurred. Andre's trajectory would have looked different if his pituitary tumor had been identified and treated in his early teens.

A Note on Inference vs. Documented Fact

This article draws on published medical literature, the 2018 HBO documentary, contemporaneous press reporting, and one attributed interview statement. Where information about Andre's specific medical history is inferred from clinical phenotype rather than documented records, that inference is labeled explicitly. No private medical records are known to have been published. The clinical inferences made here are consistent with the phenotype he displayed publicly and are grounded in the peer-reviewed literature on acromegaly natural history.